Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E23.28 EPS (ttm)1.72 Insider Own16.40% Shs Outstand2.56B Perf Week0.45%
Market Cap102.58B Forward P/E13.61 EPS next Y2.94 Insider Trans0.00% Shs Float2.30B Perf Month0.68%
Income4.47B PEG3.70 EPS next Q0.63 Inst Own10.60% Short Float0.22% Perf Quarter2.14%
Sales36.62B P/S2.80 EPS this Y4.10% Inst Trans3.83% Short Ratio1.99 Perf Half Y-2.77%
Book/sh22.23 P/B1.80 EPS next Y-3.76% ROA- Target Price50.67 Perf Year-3.29%
Cash/sh- P/C- EPS next 5Y6.30% ROE- 52W Range36.11 - 42.75 Perf YTD-2.22%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-6.39% Beta0.97
Dividend %4.15% Quick Ratio- Sales past 5Y0.50% Gross Margin69.10% 52W Low10.82% ATR0.71
Employees115631 Current Ratio- Sales Q/Q2.60% Oper. Margin17.80% RSI (14)51.01 Volatility1.23% 1.41%
OptionableYes Debt/Eq- EPS Q/Q3.90% Profit Margin14.60% Rel Volume0.57 Prev Close39.72
ShortableYes LT Debt/Eq- EarningsOct 28 BMO Payout0.00% Avg Volume2.56M Price40.02
Recom1.70 SMA20-1.02% SMA502.43% SMA2000.69% Volume1,458,800 Change0.76%
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Dec-04-16 07:00PM  Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China PR Newswire
Dec-01-16 01:56PM  Drugs Delayed By Regeneron, Sanofi Plant (REGN, SNY) at Investopedia
10:04AM  How Much Could Gilead Sciencess Revenues Fall beyond 2016?
05:00AM  Mymetics Starts Research Project with Sanofi for Influenza Vaccines PR Newswire
Nov-30-16 12:57PM  Sanofi SA (ADR) (SNY) Facing Manufacturing Headache On Two Blockbusters at Insider Monkey
09:30AM  The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays
09:30AM  NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
12:09AM  Sanofi Partnership Passes First Test With Delivery of Antibiotic Compounds at The Wall Street Journal
Nov-29-16 07:22PM  Novo's New Insulin Reduces Risk of Low Blood Sugar, Study Shows at The Wall Street Journal
04:07PM  Johnson & Johnson Reportedly Hikes Bid For Swiss Drugmaker Actelion
03:30PM  Warren Buffett's Only Dividend Stocks With 4%-Plus Yields
01:06PM  Top Research Reports for 29th November, 2016
10:41AM  Sanofi Receives Antibiotic Compounds From Partnership at The Wall Street Journal
03:37AM  Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover
Nov-28-16 04:34PM  Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
11:22AM  Heres what Fillons victory in France means for investors at MarketWatch
07:34AM  Actelion's ambitious independent-minded CEO will drive up takeover price
Nov-25-16 04:46PM  Johnson & Johnson Confirms Takeover Talks With Actelion Pharmaceuticals
Nov-24-16 07:00AM  Here is What Hedge Funds Think about Gilead Sciences, Inc. (GILD) at Insider Monkey
Nov-23-16 04:28PM  Merck Bumps Its Dividend Higher at Investopedia
11:03AM  US FDA Approves Sanofi SA (ADR) (SNY) Soliqua 100/33, Novo Nordisk A/S (ADR) (NVO) Xultophy 100/3.6 at Insider Monkey
Nov-22-16 02:58PM  Sanofi Diabetes Drug Soliqua Approved by FDA (SNY) at Investopedia
02:16PM  Dueling Diabetes Duos Won't End Price Pressure at Bloomberg
10:29AM  Shire to lease Genzyme headquarters, plans to hire another 400 at bizjournals.com
08:54AM  Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults
Nov-21-16 04:04PM  Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics
12:20PM  Regeneron Sarilumab Drug Tops Humira (REGN, SNY) at Investopedia
07:40AM  Here's Why Immune Design Should Be in Your Portfolio Now
Nov-19-16 12:22AM  [$$] Sanofi to Stop Production of Bladder-Cancer Drug BCG at The Wall Street Journal
Nov-18-16 05:27PM  Aegerion's Juxtapid Gets Pricing Authorization in Japan
03:52PM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis at Motley Fool
10:04AM  Innovative Research in Vaccines May Boost Pfizers Revenues
08:02AM  Regeneron/Sanofi's Praluent CV Outcomes Study to Continue
07:19AM  Global Survey into Perceptions of Mens Health Reveals British Men Are Not Reaping Benefits of Local Health Services and Information PR Newswire
06:18AM  Sanofi/Regeneron Present Sarilumab Data at ACR Meeting
Nov-17-16 04:01PM  New Survey Finds Men in the U.S. Want to Take Charge of Their Own Health and Wellness PR Newswire
11:04AM  How Sandoz Performed for Novartis in 3Q16
10:04AM  Performance of Novartiss Innovative Medicines Segment in 3Q16
04:50AM  No early win for Sanofi, Regeneron cholesterol drug in study
02:02AM  Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis GlobeNewswire
Nov-16-16 04:29PM  Medicines Co., Alnylam Split On Amgen-Rivaling Cholesterol-Buster
04:04PM  Changes in Novartiss Valuation for 3Q16
01:51PM  Most Analysts Rate Novartis a Buy
08:02AM  Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting GlobeNewswire
08:00AM  Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting PR Newswire
07:11AM  France sets up fund for Sanofi epilepsy drug victims Reuters
Nov-15-16 01:55PM  These Drugs Led Medicare Spending (GILD, SNY) at Investopedia
10:50AM  Sanofi, GSK expect further price pressure, more M&A under Trump Reuters
08:53AM  Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.
08:04AM  Inside AstraZenecas Oncology Segment Growth in 3Q15
Nov-14-16 05:24PM  These drugs had the highest price increases in 2015 according to the government agency that pays for them
05:09PM  Sanofi (SNY) Diabetes Drug Toujeo Positive in PK/PD Study
08:04AM  How Did the Bausch & Lomb Division Perform in 3Q16?
Nov-11-16 02:38PM  Immune Design (IMDZ) Posts Lower-than-Expected Q3 Loss
12:56PM  Sanofi Gets Hosed on MannKind Deal (SNY, MNKD) at Investopedia
10:00AM  Sanofi Presented Full Results of a PK/PD Study Comparing Toujeo® to Insulin Degludec in People With Type 1 Diabetes CNW Group
09:00AM  Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016 PR Newswire
06:00AM  Looking Abroad for Dividend Growth at Morningstar
Nov-10-16 03:32PM  Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi
12:58PM  MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing
12:04PM  Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit
11:55AM  Why MannKind Corp. Stock Skyrocketed Today at Motley Fool
Nov-09-16 07:40PM  MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind
01:22PM  The Only Number in MannKind Corporation's Q3 Results That Really Matters at Motley Fool
12:00PM  Donald Trump Election Victory Boosts Some Stocks and Sectors
Nov-08-16 05:30PM  Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October -- Here's Why at Motley Fool
01:47PM  Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance
Nov-07-16 03:35PM  World Leader in Diabetes Medication Hits 2-Year Low
07:52AM  Coverage initiated on Sanofi by Goldman
07:00AM  Buy Europe? at Morningstar
Nov-05-16 02:00PM  Half of Clinical Results Not Published (SNY, NVS) at Investopedia
11:01AM  Bernie Sanders Seeks DOJ Drug Probe (LLY, SNY) at Investopedia
Nov-04-16 04:11PM  Regeneron Bounds On EPS Beat; Stock Muzzled On Amgen Drug Brouhaha
03:50PM  Regeneron (REGN) Beats on Q3 Earnings, Misses on Sales
02:51PM  3 Things You Really Need to Know About Regeneron Pharmaceuticals' Q3 Results at Motley Fool
11:54AM  Regeneron: 'We Like the Risk Reward' at Barrons.com
08:12AM  [$$] Regeneron Revenue Growth Slows at The Wall Street Journal
08:05AM  How Does Pfizer's Dividend Stack Up? at Motley Fool
08:04AM  What Do Analysts Recommend for Novo?
08:00AM  Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Business Wire
Nov-03-16 12:06PM  Sanofi SA (ADR) (SNY) Can Thank Its Vaccines at Insider Monkey
10:04AM  How Tresiba Helps Novo Achieve Its Growth Targets
08:04AM  Victoza Dominates Global GLP-1 Class
Nov-02-16 10:05AM  Novos Dominance in Global Diabetes Market
Nov-01-16 03:20PM  Bernie Sanders is going after insulin makers over price hikes
02:57PM  3 Things You Really Need to Know About Pfizer's Q3 Results at Motley Fool
11:15AM  FDA approval delayed for Sanofi Genzymes next blockbuster at bizjournals.com
08:04AM  Merck & Co.s Animal Health Segment
08:00AM  Hedge Fund Managers Discuss Shorting Viasat (VSAT), 2U (TWOU), Long Positions in Microsoft (MSFT), Others at Insider Monkey
04:13AM  Drugmaker Sanofi hungry for deals after earnings beat
Oct-31-16 03:35PM  Pricey Cholesterol Drugs Lose Favor (AMGN, REGN) at Investopedia
10:04AM  3 Healthcare Stocks Warren Buffett Really Likes at Motley Fool
09:22AM  [$$] FDA Rejects Sanofi-Regeneron Arthritis Drug Over Plant Deficiencies at The Wall Street Journal
09:14AM  Sanofi (SNY) Beats Earnings, Revenues Rise Y/Y; Ups View
07:33AM  4 Healthcare Stocks to Buy With Dividends Yielding More Than 4% at Motley Fool
Oct-30-16 03:17PM  Will This Trend Cost Biotech Stock Investors Lots of Money? at Motley Fool
05:54AM  Regeneron, Sanofi Drug Hits FDA Snag (REGN, SNY) at Investopedia
Oct-29-16 11:40AM  Could This Look-A-Like Drug Be Merck's Next Big Seller? at Motley Fool
Oct-28-16 04:19PM  AbbVie Topples On Humira Miss; Sanofi, Novo Diverge On Insulin Panic
03:50PM  U.S. FDA spurns Sanofi, Regeneron arthritis drug over manufacturing lapse Reuters
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM